Logo
x

Search

Subscribe Now

biogen

Biogen Reports Positive Data of Felzartamab to Treat IgA Nephropathy (IgAN) at ASN Kidney Week 2024

Biogen Reports Positive Data of Felzartamab to Treat IgA Nephropathy (IgAN) at ASN Kidney Week 2024

  • October 28, 2024
Biogen’s Felzartamab Gains the US FDA’s Breakthrough Therapy Designation to Treat AMR in Kidney Transplant Recipients

Biogen’s Felzartamab Gains the US FDA’s Breakthrough Therapy Designation to Treat AMR in Kidney Transplant Recipients

  • October 11, 2024
The EC Approves Biogen’s Tofidence (Biosimilar, Roactemra) for Treating Arthritis and COVID-19

The EC Approves Biogen’s Tofidence (Biosimilar, Roactemra) for Treating Arthritis and COVID-19

  • June 26, 2024
For an Aggregate of $1.8B, Biogen Acquires Human Immunology Biosciences to Strengthen its Immunology Portfolio

For an Aggregate of $1.8B, Biogen Acquires Human Immunology Biosciences to Strengthen its Immunology Portfolio

  • May 23, 2024
Biogen Receives EMA’s CHMP Positive Opinion for Tofidence (Biosimilar, Roactemra)

Biogen Receives EMA’s CHMP Positive Opinion for Tofidence (Biosimilar, Roactemra)

  • April 25, 2024
Biogen’s Qalsody (tofersen) Receives CHMP’s Positive Opinion for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Biogen’s Qalsody (tofersen) Receives CHMP’s Positive Opinion for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

  • February 23, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.